Published On: 12/4/2024

The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR

Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study at The Liver Meeting 2024 titled, “Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.”

The study analyzed data from a real-world cohort of MASLD patients and found that those taking GLP-1 RAs had a significantly lower risk of death and progression to a more severe form of liver disease compared to non-users. Learn more about the impact of GLP-1 RAs on MASLD patient outcomes in this insightful presentation by Dr. Barritt.